Amgen Inc. $AMGN Holdings Lifted by Ferguson Wellman Capital Management Inc.

Ferguson Wellman Capital Management Inc. increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 319,238 shares of the medical research company’s stock after acquiring an additional 5,300 shares during the period. Amgen makes up about 1.5% of Ferguson Wellman Capital Management Inc.’s investment portfolio, making the stock its 22nd largest position. Ferguson Wellman Capital Management Inc.’s holdings in Amgen were worth $112,324,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Midwest Trust Co lifted its holdings in Amgen by 1.5% in the 1st quarter. Midwest Trust Co now owns 78,916 shares of the medical research company’s stock valued at $27,767,000 after acquiring an additional 1,150 shares during the last quarter. Fifth Third Bancorp grew its stake in shares of Amgen by 57.2% in the 1st quarter. Fifth Third Bancorp now owns 461,207 shares of the medical research company’s stock worth $162,276,000 after purchasing an additional 167,835 shares during the last quarter. Sovran Advisors LLC grew its stake in shares of Amgen by 4.4% in the 1st quarter. Sovran Advisors LLC now owns 5,910 shares of the medical research company’s stock worth $2,046,000 after purchasing an additional 250 shares during the last quarter. Ball & Co Wealth Management Inc. raised its holdings in shares of Amgen by 0.7% in the 1st quarter. Ball & Co Wealth Management Inc. now owns 14,254 shares of the medical research company’s stock worth $5,015,000 after purchasing an additional 94 shares in the last quarter. Finally, Simplicity Wealth LLC lifted its stake in Amgen by 7.4% during the first quarter. Simplicity Wealth LLC now owns 4,737 shares of the medical research company’s stock valued at $1,667,000 after purchasing an additional 326 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.85% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

AMGN has been the subject of a number of research reports. Wells Fargo & Company raised their target price on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Erste Group Bank restated a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $355.73.

Amgen Trading Down 0.1%

Shares of AMGN stock traded down $0.23 during trading hours on Friday, reaching $363.39. 1,632,617 shares of the stock traded hands, compared to its average volume of 2,658,015. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $391.29. The business has a fifty day moving average price of $344.81 and a 200 day moving average price of $349.32. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $196.13 billion, a PE ratio of 25.29, a PEG ratio of 3.59 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter last year, the business posted $4.90 EPS. The company’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts forecast that Amgen Inc. will post 22.32 EPS for the current year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.